<p>Siegfried has signed binding agreements to acquire the drug substance business of the Noramco Group and Extractas Bioscience from an affiliate of SK Capital Partners. The deal includes three manufacturing sites in the US and Australia, which together employ around 400 people. This acquisition will add significant US-based manufacturing capacity, strengthen Siegfried’s position in key growth segments, and enhance its offering in small-molecule drug substances. The transaction is expected to close later this year, subject to customary conditions, and will be financed through existing and new debt instruments. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Siegfried Holding AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2266092_en), on January 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Siegfried Acquires US Drug Substance Sites from Noramco Group and Extractas Bioscience